← Back to Cancer Screening

Delfi Diagnostics

High-risk lung cancer patients (smokers)

Variable
Not FDA approved
Detects: Lung cancer
Sample: Blood draw
Results: 7-10 days

Test Performance

Sensitivity

80% sensitivity

Specificity

58% specificity

Detection Method

Fragmentomics

Turnaround

7-10 days

Key Features

Lung cancer screening • Fragmentomics technology • Complements LDCT • High-risk patients

Who It's For

Important Notes

Novel fragmentomics approach to lung cancer detection. Meant to complement low-dose CT screening.

Learn more about Delfi Diagnostics

Discuss with your physician before ordering.

Visit Delfi DiagnosticsCompare All